PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The company is headquartered in Hangzhou, Zhejiang and currently employs 58 full-time employees. The company went IPO on 2025-05-27. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).
02565.HK stock price ended at $74 on 木曜日, after dropping 0.87%
On the latest trading day Jan 08, 2026, the stock price of 02565.HK fell by 0.87%, dropping from $75.15 to $74.00. During the session, the stock saw a volatility of 5.46%, with prices oscillating between a daily low of $72.30 and a high of $76.25. On the latest trading day, the trading volume for 02565.HK decreased by 94.0K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 310.5K shares were traded, with a market value of approximately $21.0B.